scholarly journals Analysis of Adverse Events Associated with Angiotensin Receptor Blockers and Hydrochlorothiazide Fixed-dose Combination: Data Mining of the Japanese Adverse Drug Event Report Database, JADER

2015 ◽  
Vol 41 (5) ◽  
pp. 347-354 ◽  
Author(s):  
Yoshihiro Noguchi ◽  
Hiroki Esaki ◽  
Shoko Asano ◽  
Takafumi Yokoi ◽  
Kazumasa Usui ◽  
...  
Keyword(s):  
Data Mining ◽  
Adverse Events ◽  
Adverse Drug Event ◽  
Angiotensin Receptor Blockers ◽  
Fixed Dose ◽  
Drug Event ◽  
Angiotensin Receptor ◽  
Event Report ◽  
Receptor Blockers ◽  
Dose Combination

Comparison of medication adherence between fixed-dose combination of angiotensin receptor blockers and statin and free-combination therapy

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
J.H Choi ◽  
J.M Choi ◽  
Y.J Jang ◽  
M Kang ◽  
S.H Lee
Keyword(s):  
Medication Adherence ◽  
Angiotensin Receptor Blockers ◽  
Female Gender ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Angiotensin Receptor ◽  
Real World Data ◽  
Persistence Rate ◽  
Receptor Blockers ◽  
Dose Combination

Abstract Background Non-adherence to angiotensin receptor blockers (ARB) or statin is one of major reasons of insufficient treatment for patients with hyperlipidemia and hypertension. We investigated whether fixed-dose combination (FDC) of ARB and statin improved adherence compared to traditional free combination (FC). Methods In this retrospective nationwide cohort study, adherence of 128,369 patients who started ARB and stain including atorvastatin or rosuvastatin between July 2014 and June 2015 was investigated. Primary endpoint was proportion of days covered (PDC) per 180 days up to day 540. Good compliance defined by PDC≥80% and persistency rate defined by patients remaining on medication were also investigated. Results Patients were 62.9 years of mean age with 48.2% female gender. Compared to FC (N=90,759, 70.7%), FDC (N=37,610, 29.3%) showed higher PDC at day 180 (86% vs 70%), 360 (77% vs 62%), and 540 (74% vs 55%, p<0.001, all). Frequency of patients with PDC≥80% was also higher in FDC compared to FC at day 180 (80.1% vs 51.8%), 360 (71.7% vs 54.2%), and 540 (69.2% vs 49.3%, p<0.001, all). Persistency rate at day 540 was higher in FDC compared to FC (50.4% vs 27.3%, p<0.001). The mean decline in PDC per 180 days were significantly lower in FDC compared to FC per 180 days (6.0% vs. 7.5%, p<0.001). Conclusions In this real-world data analysis, FDC resulted in higher medication adherence and persistence compared to FC among patients who started both ARB and atorvastatin or rosuvastatin. Persistence rate btw FDC and FC Funding Acknowledgement Type of funding source: None

scholarly journals Additional possibilities of antihypertensive therapy for metabolic syndrome

2013 ◽  
Vol 10 (2) ◽  
pp. 41-46
Author(s):  
O A Kislyak ◽  
M V Pokhilchenko
Keyword(s):  
Metabolic Syndrome ◽  
Angiotensin Receptor Blockers ◽  
Fixed Dose ◽  
Angiotensin Receptor ◽  
Metabolic Disturbances ◽  
First Choice ◽  
Receptor Blockers ◽  
Dose Combination ◽  
Symptom Complex

Metabolic syndrome (MS) is a clinical and laboratory symptom complex that encompasses abdominal obesity, carbohydrate and fat metabolic disturbances, arterial hypertension (AH), and target organ involvement. The drugs of first choice in the management of patients with AH and MS are renin-angiotensin-aldosterone system (RAAS) inhibitors, angiotensin receptor blockers (ARB) in particular, when combined with calcium antagonists (CA), which have been proven to be metabolically neutral and able to reduce the risk of type 2 diabetes mellitus. A fixed-dose combination of the ARB losartan and the CA amlodipine has additional capabilities to affect the components of MS due to higher adiponectin and lower uric acid levels.

scholarly journals Evaluation of the Association between the Use of Oral Anti-hyperglycemic Agents and Hypoglycemia in Japan by Data Mining of the Japanese Adverse Drug Event Report (JADER) Database

2014 ◽  
Vol 134 (2) ◽  
pp. 299-304 ◽  
Author(s):  
Ryogo Umetsu ◽  
Yuri Nishibata ◽  
Junko Abe ◽  
Yukiya Suzuki ◽  
Hideaki Hara ◽  
...  
Keyword(s):  
Data Mining ◽  
Adverse Drug Event ◽  
Drug Event ◽  
Event Report

scholarly journals Adverse Event Trends Associated with Over-the-counter Combination Cold Remedy: Data Mining of the Japanese Adverse Drug Event Report Database

2018 ◽  
Vol 138 (1) ◽  
pp. 123-134 ◽  
Author(s):  
Sayaka Sasaoka ◽  
Haruna Hatahira ◽  
Shiori Hasegawa ◽  
Yumi Motooka ◽  
Akiho Fukuda ◽  
...  
Keyword(s):  
Data Mining ◽  
Adverse Event ◽  
Adverse Drug Event ◽  
Drug Event ◽  
Event Report ◽  
Over The Counter ◽  
Cold Remedy
Sign in / Sign up

Export Citation Format

Share Document